145 related articles for article (PubMed ID: 37344790)
1. Node-negative colon cancer: histological, molecular, and stromal features predicting disease recurrence.
Strous MTA; van der Linden RLA; Gubbels ALHM; Faes TKE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; de Bruïne AP; Vogelaar FJ
Mol Med; 2023 Jun; 29(1):77. PubMed ID: 37344790
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
3. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q
Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846
[TBL] [Abstract][Full Text] [Related]
4. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
6. Node negative colorectal cancer patients: assesment of high-risk features on recurrence.
van der Linden RLA; Rijstenberg LL; van der Linden JC; Vogelaar FJ; Nagtegaal ID; Pruijt JFM; van de Velde CJH; van den Brule A; Bosscha K
Pathol Res Pract; 2020 Sep; 216(9):153034. PubMed ID: 32825973
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
8. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
9. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
11. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.
Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC
Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
13. The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer.
Song J; Kataoka K; Yamada T; Shiozawa M; Sonoyama T; Beppu N; Ueda K; Kuriyama S; Kanazawa A; Ikeda M; Ceelen W
Cancer Sci; 2021 Apr; 112(4):1545-1555. PubMed ID: 33484192
[TBL] [Abstract][Full Text] [Related]
14. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Ogino S; Nosho K; Kirkner GJ; Kawasaki T; Meyerhardt JA; Loda M; Giovannucci EL; Fuchs CS
Gut; 2009 Jan; 58(1):90-6. PubMed ID: 18832519
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
[TBL] [Abstract][Full Text] [Related]
17. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.
Strous MTA; Faes TKE; Gubbels ALHM; van der Linden RLA; Mesker WE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; Vogelaar FJ; de Bruïne AP
Clin Transl Oncol; 2022 Jun; 24(6):1047-1058. PubMed ID: 35064453
[TBL] [Abstract][Full Text] [Related]
18. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.
Berg M; Guriby M; Nordgård O; Nedrebø BS; Ahlquist TC; Smaaland R; Oltedal S; Søreide JA; Kørner H; Lothe RA; Søreide K
Mol Med; 2013 Sep; 19(1):286-93. PubMed ID: 23979710
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
[TBL] [Abstract][Full Text] [Related]
20. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
